GU Cancers 2020 | Nivolumab for nccRCC

Name: Nivolumab for nccRCC
Uploaded: 2020-02-15T06:10:01Z
Description: Laurence Albiges, MD, PhD, Gustave Roussy Institute, Villejuif, France discusses the methods and results of the AcSé study (NCT03012581), which investigated the use of nivolumab in rare cancers such as metastatic non-clear cell renal cell carcinoma (nccRCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Laurence Albiges • 15 Feb 2020

GU Cancers 2020

General Genitourinary Cancer Kidney Cancer Antibodies Checkpoint Inhibitors Nivolumab

AcSé

Laurence Albiges, MD, PhD, Gustave Roussy Institute, Villejuif, France discusses the methods and results of the AcSé study (NCT03012581), which investigated the use of nivolumab in rare cancers such as metastatic non-clear cell renal cell carcinoma (nccRCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.